Linoladiol-H N (Estradiol Hemihydrate, Prednisolone Sesquihydrate)

Linoladiol-H N combines estrogenic and glucocorticoid activity and is used in therapeutic areas that require hormone replacement or local anti‑inflammatory effects.

• Postmenopausal vulvovaginal atrophy: restores estrogen levels in the skin, improving elasticity and reducing dryness.
• Atopic dermatitis or eczema: reduces inflammation and pruritus through corticosteroid action.
• Psoriasis plaques: diminishes scaling and erythema by suppressing local immune response.

• Estradiol hemihydrate binds to intracellular estrogen receptors (ERα and ERβ), initiating transcription of genes that promote tissue proliferation and moisture retention. Prednisolone sesquihydrate penetrates the skin and activates glucocorticoid receptors, leading to inhibition of phospholipase A2 and suppression of pro‑inflammatory cytokine production. The combined action provides both estrogen‑mediated trophic effects and potent anti‑inflammatory activity at the site of application.

Topical application of Linoladiol‑H N may be associated with a range of local and systemic adverse reactions.

Common Side Effects

• Skin irritation: mild redness or itching at the application site.
• Burning sensation: transient warmth following application.
• Dryness or peeling: mild desquamation of the treated area.
• Hyperpigmentation: localized darkening of the skin.
• Breast tenderness: mild estrogen‑related discomfort.
• Fluid retention: slight swelling in extremities.

Serious or Rare Side Effects

• Allergic contact dermatitis: severe rash, swelling, or blistering.
• Skin ulceration: breakdown of the epidermis with possible infection.
• Systemic glucocorticoid effects: adrenal suppression with prolonged use.
• Thromboembolic events: rare clot formation associated with systemic estrogen absorption.
• Severe hypersensitivity: anaphylaxis requiring immediate medical attention.

Before prescribing Linoladiol‑H N, clinicians should consider several precautionary measures to ensure safe use.

• Contraindications: avoid in patients with known hypersensitivity to estrogen or corticosteroids.
• Pregnancy: not recommended unless benefits outweigh risks; discuss with obstetrician.
• Breast cancer history: evaluate risk due to estrogenic activity.
• Infection risk: do not apply on infected or broken skin.
• Duration: limit continuous use to the shortest period required to achieve therapeutic goals.
• Store at room temperature: keep in the original container, protect from moisture and light.

Linoladiol‑H N can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Oral anticoagulants (e.g., warfarin): estrogen may increase clotting risk, requiring close monitoring or avoidance.
• CYP3A4 inhibitors (e.g., ketoconazole): can raise systemic prednisolone levels, enhancing glucocorticoid effects.
• Hormonal contraceptives: combined estrogen exposure may elevate thrombotic risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive GI irritation when systemic absorption occurs.
• Antidiabetic agents: systemic corticosteroid absorption may raise blood glucose levels.
• Live vaccines: systemic corticosteroid effect may reduce vaccine efficacy.